4th LION Masterclass (14th to 16th May 2020) Online live webinar - Scientific Agenda				
	Thursday 14th May 2020	Friday 15th May 2020	Saturday 16th May 2020	
530 - 545 pm	Sponsored Session A	Special Demonstration	Sponsored Session G Part 1	
Sponsor	Intas	Kavina Creations	Astra Zeneca	
	Indian Experience with	Virtual Conference	Case based Discussion-	
	Novel Formulation of	Capabilities Walkthrough	How to manage a Stage-III	
Topic	Docetaxel in HSPC		NSCLC patient	
Speaker/Moderator	Chandan Das		Kumar Prabhash	
545 - 600 pm	Sponsored Session A	Sponsored Session D	Sponsored Session G Part 2	
Sponsor	Intas	OncoStem	Astra Zeneca	
	Indian Experience with	Immunotherapy options for	Case based Discussion-	
	Novel Formulation of	Breast Cancer - Exciting	How to manage a Stage-III	
Topic	Docetaxel in HSPC	results from I-SPY 2 study	NSCLC patient	
Speaker/Moderator	Chandan Das	Chirag Desai	Kumar Prabhash	
600 - 640 pm	Session 1 - Are all IO drugs the same?	Session 5 - Breast Cancer and IO	Session 9 - Lung Cancer &	
600 - 640 pm	the same!	10	IO (part2) Talk (10 mins) - Does	
			bevacizumab still have a	
	Talk (10 mins) - Why CPS in	Talk (10 mins) - IO in early	role in Mx of Non	
Topic	some and TPS in others?	stage TNBC	Squamous Lung Cancer?	
Speaker	Nikhil Ghadyalpatil	Prashant Mehta	Ankur Bahl	
		Panel Discussion (20 mins) -		
	Panel Discussion (20 mins) -	Metastatic Breast Cancer - IO	Panel Discussion (20 mins) -	
	Biomarker Update - PDL1,	in first and subsequent lines	Role of consolidation with	
Topic	MSI, others	of Mx	10	
Moderator	<b>Chirag Desai</b>	Amit Rauthan	Randeep Singh	
	Audience Voting (5 mins)	Audience Voting (5 mins)	Audience Voting (5 mins)	
<b>Expert Conclusion</b>	Hemant Malhotra (5 mins)	Govind Babu (5 mins)	Chetan Deshmukh (5 mins)	
640 - 700 pm	Sponsored Session B	Sponsored Session E	Sponsored Session H	
Sponsor	Dr Reddy's	Novartis	Biocon	
		Overall Survival in HR+ HER2-	Management of Locally	
	<b>Tackling Common Toxicities</b>	aBC: The difference is more	Advance Head and Neck	
Subject	in Targeted Therapy	life	Cancer: An Indian Context	
Speaker	Sandeep Batra	Joydeep Ghosh	Neera Gupta	
		_	Joint Session (IASCO, ICON	
700 - 720 pm	Sponsored Session C	Sponsored Session F	& ISMPO)	
Sponsor	Novartis	1 % 1	Geriatric Oncology Session	
			Special Considerations for	
	Dedefining war to 11 DD 67	Optimising the treatment	the elderly during	
Subject	Redefining survival in BRAF mutated melanoma	sequencing in multiple	personalized oncology	
Subject		myeloma management.	therapy	
Speaker/Moderator	Bivas Biswas	Hemant Malhotra	Amish Vora	

	Session 2 - Lessons from	Session 6 - Genitourinary &	
720 - 800 pm	Melanoma	Ю	Session 10 - CRC & IO
			Talk (10 mins) - MDR
	Talk (10 mins) - lessons from		monitoring in CRC patients
Topic	BRAF inhibition	Panel 1 (15 mins) - IO in RCC	- is this the way forward?
Speaker/Moderator	Prasad Narayanan	Vineet Talwar	Vamshi Krishna
	Panel Discussion (20 mins) -		Panel Discussion (20 mins) -
Tania	IO role in adjuvant vs		Mx of first line in frail
	metastatic Mx, mucosal vs	D. (12 (45 (1)) 10 (1)	patients with high MSI,
	visceral melanoma, single	Panel 2 (15 mins) - IO in	combination or single
Topic	agent vs combi	Urothelial malignancies	agent IO
Moderator	Rejiv Rajendranath	Manish Singhal	Shyam Aggarwal
	Audience Voting (5 mins)	Audience Voting (5 mins)	Audience Voting (5 mins)
Francis Conclusion	Raghunadhrao Digumarti (5	AV Void (F mains)	Chaliban Batil (Finning)
Expert Conclusion	mins)	AK Vaid (5 mins)	Shekhar Patil (5 mins)
	Consider 2 Hond & Noch 1st		Cassian 11 Other Cl
	Session 3 - Head & Neck 1st	Session 7 - NSCLC and IO	Session 11 - Other Gl
900 94F mm	Line Immunotherapy Supported by Merck	(part 1)	Malignancies & IO Supported by Eli Lilly
800 - 845 pm	Supported by Werck	(part 1)	Talk (10 mins) - Options in
	Talk (10 mins) - Role of CPS in	Talk (10 mins) - Single Agent	Management of second
Topic	SCCHN	IO vs IPI/Nivo combination	line Advanced Ca Stomach
Speaker	Ghanashyam Biswas	Vikas Talreja	Rahul Sud
эрсиксі	Panel Discussion (25 mins) -	vinas rairėja	Runai Sud
	poor RR to single agent,	Panel Discussion (25 mins) -	
	single agent vs combination,	Spoilt for choice in 1st line,	
	numerically lower RR of	who gets what, PDL1 testing	Panel Discussion (25 mins)
	comibi vs CT+cetuximab, role	and pembro/ atezo,	IO vs TKI in HCC - is there
	in platinum refractory, any	availability of SP142, Rx on	sufficient evidence for lack
Topic	real benefit	PD	of benefit
Moderator	Kumar Prabhash	Ullas Batra	T Raja
	Audience Voting (5 mins)	Audience Voting (5 mins)	Audience Voting (5 mins)
<b>Expert Conclusion</b>	Amit Agarwal (5 mins)	R Rangarao (5 mins)	Pankaj Goyal (5 mins)
845 - 900 pm	Break	Break	Break
		Session 8 - COVID-19	
	Session 4 - Busting Stress	Pandemic & MedicoLegal	Session 12 - IO Rx during
900 - 930 pm	during COVID-19 Pandemic	issues	COVID-19 pandemic
Moderator	AA Ranade	Purvish Parikh	Chaturbhuj Agrawal
	Samita Ghadyalpatil, Babita		Dinesh Doval, Krishna
	Hapani, Prashant Mehta,	Subhash Ranjan, Sumant	Kumar Ratnam, Mangesh
	Shyam Aggarwal, Chirag	Gupta, Lalit Mohan Sharma,	Kamath, Vineet Govinda
Daniellate	Desai, Shailesh Bondarde &	Malay Nandy, Avinash Talele	Gupta, Indu Bansal &
Panelists	Bharatsingh Bhosale	& Ashish Singh	Krishna Mohan MVT
Ouganizara	Surg Cmde Dr Subhash	TD Cohoo	Dumiele Devilde
Organizers	Ranjan	TP Sahoo	Purvish Parikh